Innoviva, Inc..
INVA.US | Activities of head offices
Innoviva, Inc. is a biopharmaceutical company focused on commercializing and developing respiratory medicines. The company partners with pharmaceutical companies to develop and commercialize inhaled respiratory therapies. Innoviva receives royalties and other payments from its partners based on sale...Show More
Better Health for All
30
Innoviva's core business focuses on developing and commercializing treatments for respiratory diseases and serious infections, contributing positively to health outcomes. Their portfolio includes antibiotics like ZEVTERA and XACDURO, addressing drug-resistant infections
1
,
2
. The FDA accepted the New Drug Application for Zoliflodacin, a potential treatment for gonorrhea, with GARDP ensuring access in low- and middle-income countries
3
,
4
. Phase 3 trials of Zoliflodacin showed it was generally well-tolerated
5
,
6
. Innoviva invested $34.7 million in strategic healthcare assets in Q1 2025
7
. However, the article from the Access to Medicine Foundation highlights the lack of robust plans for affordability in LMICs for most projects
8
. Given the materiality analysis and the focus on developing treatments, a score significantly below 30 would be illogical. **Score: 30, Confidence: 70**
Fair Money & Economic Opportunity
0
Innoviva, Inc. is a biopharmaceutical company focused on developing and commercializing respiratory medicines.
1
The company's business model does not involve lending, insuring, moving, or storing money for consumers, nor does it offer consumer credit products or financial services.
2
Consequently, all KPIs under the 'Fair Money & Economic Opportunity' value, which are designed for financial institutions, are not applicable to Innoviva's operations.
Fair Pay & Worker Respect
0
The company's business model, described as managing partnerships and receiving royalties from IP-licensing rather than manufacturing or directly selling drugs, aligns with the 'N/A – not applicable to holding or IP-licensing structures' criterion for the CEO median pay ratio KPI. Although a 6:1 ratio is reported, the nature of the business suggests this metric is not meaningfully comparable to companies with traditional, larger workforces.
1
Fair Trade & Ethical Sourcing
0
Innoviva, Inc. operates as a biopharmaceutical company that manages partnerships and receives royalties, rather than manufacturing or directly selling drugs. As such, the company does not procure or trade physical commodities, nor does it have a direct supply chain for materials or a supplier base requiring welfare or sourcing audits. Consequently, all KPIs related to fair trade and ethical sourcing are not applicable to its business model, and no relevant data was found in the provided articles.
1
Honest & Fair Business
0
No specific, quantitative evidence was found across the provided articles to assess Innoviva, Inc. against any of the 'Honest & Fair Business' KPIs. The articles primarily focus on executive and board member biographies and general statements of commitment to corporate governance, without providing data on regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification of ethical claims.
1
Kind to Animals
0
No specific, concrete evidence regarding Innoviva, Inc.'s performance on animal welfare, animal testing, humane certifications, wildlife conservation, ethical sourcing, or related policies was found in the provided articles.
1
The articles primarily contained financial and corporate filing details, explicitly stating a lack of information on animal welfare metrics.
2
No War, No Weapons
0
Innoviva, Inc. is a biopharmaceutical company focused on respiratory medicines, and its core business model does not involve any defense or arms-related activities.
1
The provided articles consistently state that there is no mention of revenue from arms or defense contracts, dual-use technology, controversial weapons, peace technology investment, or procurement from conflict zones.
2
Therefore, for KPIs related to these activities, the company is assessed as 'N/A – no defense or arms-related activities in core business' or similar 'N/A' categories.
Planet-Friendly Business
0
Innoviva, Inc. is a biopharmaceutical company that primarily manages partnerships and receives royalties, rather than directly manufacturing or selling drugs.
1
The provided articles, including financial summaries and ESG risk ratings, do not contain specific, quantifiable data points for any of the environmental performance indicators in the rubric for Innoviva, Inc.
2
Information regarding sustainability targets and initiatives found in one article pertains to 'Innovia Films,' which is a distinct entity from 'Innoviva, Inc.'
3
Therefore, there is no direct evidence to assess Innoviva, Inc.'s performance against the Planet-Friendly Business KPIs.
Respect for Cultures & Communities
0
Innoviva's business model, focused on biopharmaceutical partnerships and royalties without direct manufacturing or sales, suggests that certain cultural impact KPIs are not applicable. No cultural appropriation incidents are explicitly mentioned in the provided documents, and no cultural impact assessment protocol is mentioned, aligning with a 'not applicable' status for these KPIs.
1
The company provides several grievance mechanisms, including a 24/7/365 hotline managed by an outside vendor, a Legal/Compliance Department, Human Resources, and direct mail.
2
These mechanisms are for reporting illegal or unethical behavior and accounting concerns, which are standard for corporate governance but are not specifically designated for community concerns.
3
The company's Code of Business Conduct advises immediate notification to the Legal/Compliance Department for cultural incidents, indicating a basic response framework.
4
Safe & Smart Tech
0
Innoviva, Inc. reported no material cybersecurity incidents or risks identified for the year ended December 31, 2024.
1
The company has established policies and processes for assessing, identifying, and managing cybersecurity risks, which are integrated into its overall risk management system.
2
Annual risk assessments are conducted, including identification of internal and external risks, their likelihood, potential damage, and the sufficiency of safeguards.
3
Safeguards are redesigned, implemented, maintained, monitored, and tested to minimize risks.
4
The board of directors oversees risk management, including cybersecurity, directly and through the audit committee.
5
Executive officers and the information security team are responsible for daily risk management and provide briefings to the audit committee and board.
6
Zero Waste & Sustainable Products
0
No specific, concrete evidence was found in the provided articles regarding Innoviva, Inc. (INVA.US) performance across any of the 'Zero Waste & Sustainable Products' KPIs.
1
Information related to other companies (Innovia Films, Innovive), general industry trends, or EU regulations was excluded as it does not pertain to INVA.US directly. The company's business model, focused on royalties from partners rather than direct manufacturing or sales, means many of these KPIs would apply to its partners, but no evidence links INVA.US to specific actions or data from its partners.
2